Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Edyta Maria Urbanska; Eric Santoni-Rugiu; Linea Cecilie Melchior; Jonathan Frederik Carlsen; Jens Benn Sørensen

doi:10.1016/j.cllc.2020.04.012

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Edyta Maria Urbanska, Eric Santoni-Rugiu, Linea Cecilie Melchior, Jonathan Frederik Carlsen, Jens Benn Sørensen

6 Citations (Scopus)

Original language	English
Journal	Clinical Lung Cancer
Volume	22
Issue number	4
Pages (from-to)	e528-e532
ISSN	1525-7304
DOIs	https://doi.org/10.1016/j.cllc.2020.04.012
Publication status	Published - Jul 2021

Keywords

Alectinib hepatotoxicity
ALK
CNS efficacy of brigatinib
CNS relapse
Dose-escalated brigatinib

Access to Document

10.1016/j.cllc.2020.04.012

Cite this

Urbanska, E. M., Santoni-Rugiu, E., Melchior, L. C., Carlsen, J. F., & Sørensen, J. B. (2021). Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. Clinical Lung Cancer, 22(4), e528-e532. https://doi.org/10.1016/j.cllc.2020.04.012

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. / Urbanska, Edyta Maria ; Santoni-Rugiu, Eric ; Melchior, Linea Cecilie et al.
In: Clinical Lung Cancer, Vol. 22, No. 4, 07.2021, p. e528-e532.

Research output: Contribution to journal › Journal article › Research › peer-review

Urbanska, EM , Santoni-Rugiu, E , Melchior, LC , Carlsen, JF & Sørensen, JB 2021, 'Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery', Clinical Lung Cancer, vol. 22, no. 4, pp. e528-e532. https://doi.org/10.1016/j.cllc.2020.04.012

Urbanska EM , Santoni-Rugiu E , Melchior LC , Carlsen JF, Sørensen JB. Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. Clinical Lung Cancer. 2021 Jul;22(4):e528-e532. doi: 10.1016/j.cllc.2020.04.012

Urbanska, Edyta Maria ; Santoni-Rugiu, Eric ; Melchior, Linea Cecilie et al. / Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. In: Clinical Lung Cancer. 2021 ; Vol. 22, No. 4. pp. e528-e532.

@article{1448f31b9d4e4e6fbe483897ea3a3a88,

title = "Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery",

keywords = "Alectinib hepatotoxicity, ALK, CNS efficacy of brigatinib, CNS relapse, Dose-escalated brigatinib",

author = "Urbanska, {Edyta Maria} and Eric Santoni-Rugiu and Melchior, {Linea Cecilie} and Carlsen, {Jonathan Frederik} and S{\o}rensen, {Jens Benn}",

year = "2021",

month = jul,

doi = "10.1016/j.cllc.2020.04.012",

language = "English",

volume = "22",

pages = "e528--e532",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc",

number = "4",

}

TY - JOUR

T1 - Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

AU - Urbanska, Edyta Maria

AU - Santoni-Rugiu, Eric

AU - Melchior, Linea Cecilie

AU - Carlsen, Jonathan Frederik

AU - Sørensen, Jens Benn

PY - 2021/7

Y1 - 2021/7

KW - Alectinib hepatotoxicity

KW - ALK

KW - CNS efficacy of brigatinib

KW - CNS relapse

KW - Dose-escalated brigatinib

UR - http://www.scopus.com/inward/record.url?scp=85087701448&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.04.012

DO - 10.1016/j.cllc.2020.04.012

M3 - Journal article

C2 - 32651064

SN - 1525-7304

VL - 22

SP - e528-e532

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Keywords

Access to Document

Other files and links

Cite this